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Objectives The study investigated the efficacy and safety of a balloon expandable, sirolimus-eluting stent (SES) in patients
with symptomatic infrapopliteal arterial disease.
Background Results of infrapopliteal interventions using balloon angioplasty and/or bare stents are limited by a relatively high
restenosis rate, which could be potentially improved by stabilizing the lesion with a SES.
Methods Two hundred patients (total lesion length 27  21 mm) were randomized to infrapopliteal SES stenting or percu-
taneous transluminal balloon angioplasty (PTA). The primary endpoint was 1-year in-segment binary restenosis
by quantitative angiography.
Results Ninety-nine and 101 patients (mean age 73.4 years; 64% diabetics) were randomized to SES and PTA, respec-
tively (8 crossover bailout cases to SES). At 1 year, there were lower angiographic restenosis rates (22.4% vs.
41.9%, p  0.019), greater vessel patency (75.0% vs. 57.1%, p 0.025), and similar death, repeat revascularization,
index-limb amputation rates, and proportions of patients with improved Rutherford class for SES versus PTA.
Conclusions SES implantation may offer a promising therapeutic alternative to PTA for treatment of infrapopliteal peripheral
arterial disease. (J Am Coll Cardiol 2012;60:2290–5) © 2012 by the American College of Cardiology
Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.08.989Patients with critical limb ischemia may have multiple
comorbidities rendering them unsuitable for open bypass
surgery. Up to one-third, mainly those with diabetes mel-
litus or compromised renal function, have isolated infrapo-
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territory. Four small prospective single-center studies (3–6)
showed that the CYPHER SELECT sirolimus-eluting
stent (SES) (Cordis, Johnson & Johnson, Bridgewater, New
Jersey) reduced the incidence of restenosis and repeat
intervention in below-the-knee lesions for up to 1 year
(3–7). Later studies confirmed and expanded these findings
(8–11).
The ACHILLES prospective multicenter randomized
trial was designed to compare the performance of SES and
PTA in de novo and restenotic infrapopliteal lesions using
angiographic 1-year in-segment binary restenosis rate as
primary endpoint.
Methods
The ACHILLES trial was conducted in 16 centers in 9
European countries. It was conducted according to the
Declaration of Helsinki and Good Clinical Practice with
oversight by a Data Safety Monitoring Board, protocol
approval by the Ethical Committee of each clinical institu-
tion, and written informed consent from each patient. A
Clinical Events Committee adjudicated adverse events, an
independent core laboratory (BioImaging, Leiden, the
Netherlands) analyzed arteriographic and radiographic im-
ages, and the investigational centers analyzed the duplex
ultrasound studies. Data management was conducted by a
contract research organization (Clinquest Europe, Leiden,
the Netherlands) independent from the sponsor (Cordis,
Johnson & Johnson, Bridgewater, New Jersey).
Study design and endpoints. The ACHILLES trial com-
pared the clinical utility of SES with PTA in patients with
symptomatic peripheral arterial disease (PAD; Rutherford
class 3 to 5) manifested in the infrapopliteal arterial
territory.
The primary endpoint was 12-month in-segment binary
restenosis (in and/or 5 mm proximal/distal to treated
length) determined by quantitative angiography. Primary
patency was defined as absence of clinically driven target
lesion revascularization (TLR) and binary restenosis as-
sessed by angiography or duplex ultrasonography (DUS) if
angiography was unavailable. Pre-specified secondary end-
points included death, repeat revascularization, index-limb
amputation, various angiographic parameters, stent frac-
tures (plain x-ray film assessment) at 12 months, and
index-limb wound status at screening, 6 weeks, and 6 and
12 months (the latter assessment will be published sepa-
rately). The primary endpoint for the diabetic population,
and the cumulative event rate for the composite of death,
TLR, bypass, and Rutherford class 4 were analyzed
post-hoc.
Patient selection. The trial enrolled patients with infrapo-
pliteal PAD. Reasons for exclusion were significant stenoses
(50%) distal to the target lesion that might require
revascularization or impede runoff; angiographically evident
thrombus or history of thrombolysis within 72 h; untreatedlesions (75% stenosis) in the
common or external iliac; com-
mon or superficial femoral and
popliteal artery; infrapopliteal
trifurcation lesions requiring 2-
or 3-branch treatment; stent
placement across or within 1 cm
of the knee joint or in an artery
subject to external compression;
prior stenting within the target
vessel(s) or aneurysm in the SFA
or popliteal artery; history of
thrombophlebitis, deep venous thrombosis, or impaired
renal function (Cr 2.5 mg/dl); life expectancy 12
months; or known intolerance to antiplatelet medication.
The Online Appendix includes a full list of inclusion/
exclusion criteria and secondary endpoints.
Randomization. Eligible patients were randomized on a
1:1 basis using a numbered envelope system to either PTA
or SES implantation. To minimize crossover from PTA to
stenting, further balloon post dilation(s) was encouraged in
case of unsatisfying immediate PTA results before bailout
stent placement.
Interventional procedure and pharmacological regimen.
Following standard interventional technique, patients in the
SES group received up to 4 CYPHER SELECT stents
(lengths 8 to 33 mm; diameters 2.5, 3.0, and 3.5 mm)
within 1 vessel, or up to 2 stents per lesion in 2 different
vessels, up to a total lesion length of 120 mm in a 1.1:1
stent-to-artery diameter ratio. Although performed rarely,
treatment of distal lesions was allowed during the index
procedure. Pre-dilation, albeit left to the operator’s discre-
tion, was mandatory for severely calcified lesions and
chronic total occlusions. The selection of the angioplasty
balloon was left to the operator’s discretion. Fluoroscopic
documentation of balloon inflation was mandatory to allow
for treatment segment identification. Aspirin and a loading
dose of 300 mg of clopidogrel (or 2  250 mg ticlopidine)
were given pre-procedure. Intraprocedural heparin was used
to maintain activated clotting time levels 250 s, and
low-dose aspirin and—in the SES arm only—75 mg clopi-
dogrel (or 2  250 mg ticlopidine) were maintained for 6
months.
Clinical and angiographic follow-up. In follow-up visits,
planned at 6 weeks, 6 months, and 12 months post–index
procedure, Rutherford classification (treadmill test–based
clinical assessment), ankle-brachial index, duplex ultra-
sound, and index-limb wound status were assessed. Quan-
titative angiography and plain x-ray film imaging of the
index limb were performed at baseline and at 12 months.
Statistical analysis. Analyses were performed on the
intent-to-treat and as-treated population, although only
intent-to-treat results are presented here. Mean value,
standard deviation, median, and range were used for con-
tinuous variables, and count and percentages for categorical
Abbreviations
and Acronyms
PAD  peripheral arterial
disease
PTA  percutaneous
transluminal balloon
angioplasty
SES  sirolimus-eluting
stent(s)
TLR  target lesion
revascularizationvariables. Continuous variable normality was checked with
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a nonparametric Wilcoxon–Mann-Whitney test was used to
assess group differences. Event-specific adjusted denomina-
tors were employed for cumulative rates and included all
patients experiencing an event within 360 days, and those
not experiencing an event within 360 days and with at least
330 days of follow-up after index procedure. Kaplan-Meier
estimates and log-rank test survival methods were used to
assess death, TLR, amputation, and Rutherford class 4.
All statistical analyses were performed with SAS (version
9.1 or higher, SAS Institute, Cary, North Carolina).
Sample size estimation. Assuming a binary restenosis rate
of 45% and 20% for the PTA and SES groups (56% relative
reduction), 61 evaluable lesions (or 56 patients, assuming an
average lesion/patient ratio of 1.1 and between-lesion inde-
pendence) per group will have approximately 80% power
(2-sided 5% significance level; lesion-based analysis;
2-group continuity corrected c2 test). The total sample size
per group was increased to 94 lesions (n 86) to account for
a potential dropout of 35%, and finally to 100 patients to
accommodate potential crossovers.
Results
Patient population and lesion complexity. Two hundred
patients were enrolled between March 2008 and January
2010 and randomized to receive SES (n  99 patients,
113 lesions) or PTA (n  101, 115 lesions) (patient flow
in Fig. 1). The 12-month clinical follow-up was available
or 154 of 200 patients (77%): 23 of 200 (11.5%) patients
Figure 1 Patient Flow Through the Study: Intent-to-Treat Popul
PTA  percutaneous transluminal balloon angioplasty; SES  sirolimus-eluting steied, 7 of 200 (3.5%) withdrew consent, and 16 of 2008%) were lost to follow-up. Evaluable angiograms were
vailable for 67 of 113 (59.3%) and 74 of 115 (64.3%)
esions in the SES and PTA arms, respectively. For
etermination of patency, DUS data were used when
ngiography was unavailable.
Patients in both arms were well matched according to
aseline characteristics and clinical risk factors (Table 1).
ean age was 73.4 years, 64.5% were diabetic, 65.0% had a
istory of PAD, 72.9% had a history of hyperlipidemia, and
0.5% had arterial hypertension.
Lesions treated had a high degree of complexity (Table 2):
he average reference-vessel diameter was 2.6 mm, the mean
otal lesion length was 26.9 mm, and 81.3% of stented
atients had at least 1 total occlusion. Highly calcified
esions were present in 15% of patients.
Patient DemographicsTable 1 Patient Demographics
All Patients
(n  200)
SES
(n  99)
PTA
(n  101)
p Value
(SES vs. PTA)
Age, yrs 73.4 8.8 72.4 9.4 74.3 8.2 0.117
Male, % 71.5 67.7 75.2 0.274
Diabetes, % 64.5 64.6 64.4 1.000
History of PAD, % 65.0 66.7 63.4 0.658
History of CAD, % 45.0 45.5 44.6 1.000
Hypertension, % 90.5 89.9 91.1 0.813
Hyperlipidemia, % 72.9 77.6 68.3 0.154
Smoker, % 32.3 38.4 26.3 0.094
Values are mean  SD or %.ation
nt(s).CAD  coronary artery disease; PAD  peripheral arterial disease; PTA  percutaneous
transluminal balloon angioplasty; SES  sirolimus-eluting stent(s).
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There was an average of 1.8 stents/patient and mean stent
length per patient was 27.6 mm. Eight patients crossed over
from PTA to bailout stenting.
Angiographic and clinical endpoints. The primary end-
point, 1-year in-segment binary restenosis by quantitative
angiography, was reached by 22.4% and 41.9% of patients in
the SES and PTA groups (p  0.019), respectively (Fig. 2).
This difference was even more significant in the diabetic
subgroup of 98 patients (17.6% vs. 53.2%, p  0.001).
Patient- and lesion-based analyses, patients with single or
multiple lesions, or intent-to-treat and as-treated analyses
yielded similar comparative results.
Table 3 summarizes the angiographic results. Vessel
atency (absence of50% diameter stenosis by angiography
or duplex if angiogram missing and freedom from clinically
driven TLR) was higher in SES versus PTA (75% vs.
57.1%, p  0.025). Regarding clinical endpoints (Table 4),
Baseline Lesion Characteristics and ProceduralTable 2 Baseline Lesion Characteristics and
SE
(n  113
Total lesion length, mm 26.9
Reference vessel diameter, mm 2.6
CTO, % 81
Total length of CTO,* mm 6.7
Restenotic lesions, % 5
Calcification (moderate/severe), % 15
Pre-procedure stenosis, % 68.8
Post-procedure stenosis, % 13.3
Device success,† % 95
Lesion success,‡ % 100
Procedure success,§ % 94
Values are mean  SD or %. *Investigator reported. †Achievement of
‡Achievement of 50% residual in-stent or in-balloon diameter steno
diameter stenosis of50% using any percutaneous method, without t
removal or the subject leaves the cath lab, whichever earlier.
CTO  chronic total occlusion; other abbreviations as in Table 1.
Figure 2 Angiographic Results at 12-Month Follow-Up
Primary endpoints for the intention-to-treat (ITT) population (A), the as-treated poprates of death (10.1 vs. 11.9%, p  0.822), clinically driven
TLR (10.0 vs. 16.5%, p  0.257), and index-limb ampu-
tation (13.8 vs. 20.0%, p  0.307) were all numerically
lower in the SES arm. Only 1 minor type II stent fracture
was identified by plain x-ray film imaging.
Freedom from death, TLR, bypass/amputation, and
Rutherford class4 (Fig. 3) was higher in SES versus PTA
(p  0.0284).
Mean baseline Rutherford class was 4.1  0.9 and 4.0 
0.9 in the stent and PTA arms, respectively. Ischemic
symptoms of PAD improved gradually in both groups,
numerically more in the SES arm. The proportion of
patients in SES versus PTA arms with Rutherford class
improvement was 61.54% (56 of 91) versus 61.54% (56 of
91) at 6 weeks (p  1.00), 71.43% (55 of 77) versus
62.03% (49 of 79) at 6 months (p  0.2141), and 76.06%
(54 of 71) versus 67.11% (51 of 76) at 1 year (p 
0.2315), respectively.
meterscedural Parameters
s)
PTA
(n  115 Lesions) p Value
26.8 21.3 0.913
2.6 0.6 0.894
75.4 0.334
11.0 22.4 0.114
1.8 0.171
15.2 1.000
74.0 19.0 0.039
25.9 15.2 0.001
58.2 0.001
96.9 0.103
92.9 0.758
residual diameter stenosis of 30%, using the assigned device only.
g any percutaneous method. §Successful recanalization with a final
rrence of a serious adverse event up to the catheter sheath introducer
(B), and the diabetic subpopulation (C). Abbreviations as in Figure 1.ParaPro
S
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Interventional treatment of infrapopliteal arteries has be-
come an alternative to surgical revascularization. The
ACHILLES trial sought to investigate SES for this indi-
cation and to compare its safety and performance with that
of balloon angioplasty. The study is positive for the angio-
graphic primary endpoint with a lower 1-year restenosis rate
for SES over PTA (22.4% vs. 41.9%, p 0.019) for patients
with total lesion lengths below 120 mm, a difference that is
even larger for diabetics (SES: 17.6% vs. PTA: 53.2%, p 
0.001) who constitute the majority of patients with periph-
eral infrapopliteal disease, overall and in this study (65%).
The ACHILLES trial also confirms the technical feasibility
of stenting in the infrapopliteal territory with higher
device-, lesion-, and procedure-based success rates for the
stent arm. Although the study protocol discouraged cross-
over for bailout, 8 patients in the PTA arm needed stents,
which is probably still under-reflecting the incidence of
bailout stent placement in routine practice.
Although the study was not powered for such compari-
sons and advanced disease stages with multiple comorbidi-
ties confound the analysis of clinical parameters, the safety
outcomes generally favored the SES arm numerically in-
cluding most importantly clinically driven TLR.
Previous related studies showed better 1-year primary
patency and symptomatic improvement for a non-polymer
Angiographic Endpoints at 12-Month Follow-UpTable 3 Angiographic Endpoints at 12-Month Follow-Up
SES
(n  99)
PTA
(n  101) p Value
In-segment measurements*
Binary restenosis (primary endpoint) 15/67 (22.4) 31/74 (41.9) 0.019
Percent diameter stenosis, % 35.2 21.7 48.3 25.4 0.001
Minimal lumen diameter, mm 1.7 0.7 1.4 0.8 0.044
Late lumen loss, mm 0.5 1.1 0.4 1.0 0.979
In-lesion measurements†
Percent diameter stenosis, % 34.3 24.5 47.1 25.7 0.002
Minimal lumen diameter, mm 1.7 0.7 1.4 0.8 0.016
Late lumen loss, mm 0.7 0.8 0.6 0.7 0.833
Values are n (%) or mean  SD. *Within the stent or balloon area  adjacent 5 mm in both
directions. †Within the stent or balloon area.
Abbreviations as in Table 1.
Clinical Endpoints at 12-Month Follow-UpTable 4 Clinical Endpoints at 12-Month Follow-Up
SES
(n  99)
PTA
(n  101) p Value
Death* 10/99 (10.1) 12/101 (11.9) 0.822
TLR (clinically driven) 8/80 (10.0) 14/85 (16.5) 0.257
TVR – non-TLR, count 5/78 (6.4) 2/84 (2.4) 0.263
Vessel patency† 54/72 (75.0) 44/77 (57.1) 0.025
Index limb amputation 11/80 (13.8) 17/85 (20.0) 0.307
Stent fractures 1/113 (0.9) 0/0 (0) —
Values are n (%). Patient-based analyses, except for the stent fracture rate (lesion-based). *Up to
360 days. †Absence of hemodynamically relevant restenosis and of clinically driven TLR. Reste-
nosis is assessed angiographically, and by Duplex ultrasound for patients without available
angiographic follow-up.
TLR  target lesion revascularization; TVR  target vessel revascularization.SES versus bare-metal stent in a 161-patient randomized
study (10), and higher 12-month index-vessel patency and
numerically lower restenosis for the everolimus-eluting stent
versus bare-metal stent in a 140-patient randomized study
of critical limb ischemia patients (11). Other studies showed
3-year limb salvage and survival rates exceeding those of
historical controls for drug-eluting stents (83% SES, 17%
paclitaxel-eluting stent; 106-patient study) (12), and a
1-year 77.4% in-stent binary restenosis rate and 30% pri-
mary patency rate despite an initial 100% technical success
rate for paclitaxel-eluting stent (29-patient series) (13).
In summary, based on better angiographic and similar
safety outcomes to PTA the ACHILLES trial supports the
use of the SES in below-the-knee arteries as a therapeutic
option for patients with infrapopliteal disease and critical
limb ischemia. Randomized studies with other available
drug-eluting stents and longer follow-up observations are
required to further substantiate outcome differences, dura-
bility, and cost-effectiveness of this strategy.
Study limitations. The study encompassed mainly focal
lesions with an average total length of 27 21 mm (allowed
maximum was 120 mm). Therefore, its findings may not
equally apply to longer lesions. DUS studies were closely
monitored but not analyzed by core laboratory and not
correlated with arteriography if available. While they were
not part of the primary endpoint analysis, limitations of
their accuracy could have impact on vessel patency. There
was a high rate of patients lost to follow-up mainly to death
and withdrawal of consent. Although not unexpected, not
exceeding the assumptions for sample size estimation, and
comparable between arms, this may have introduced bias.
The population included in the study poses significant
challenges in terms of follow-up and outcome interpretation
and relevance; nevertheless, the results of this study are
consistent and compare favorably with those of previous
ones using similar or different therapeutic approaches; they
Figure 3 Freedom From Death, Target Lesion Revascularization,
Bypass, Amputation, and Rutherford Class >4
The SES group had significantly greater freedom from the composite endpoint
relative to the balloon angioplasty group. Abbreviations as in Figure 1.
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is usually not amenable to surgical intervention, there is a
clinical need to improve on outcomes from medical therapy
alone, and the less invasive nature of endovascular therapy
makes it theoretically a more attractive alternative for
patients with critical limb ischemia and multiple comorbidi-
ties associated with higher mortality. Only 1 of the available
SES was tested in this study; nevertheless, study results may
apply similarly to other SES, which remains to be
investigated.
Conclusions
The SES yields 1-year clinical and angiographic outcomes
that are superior in efficacy and similar in safety for
infrapopliteal arterial disease compared with PTA. Its use
may constitute an attractive alternative for patients with
claudication and critical limb ischemia. Treatment of the
latter condition, particularly achievement of limb salvage,
remains challenging regardless of approach given the mul-
tiple factors that affect disease pathogenesis and progression;
endovascular intervention only addresses some of them and
should be considered as part of a multispecialty intervention.
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expanded Methods section, please see the online version of this article.
